Study identifier:D7420C00002
ClinicalTrials.gov identifier:NCT06160414
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
Healthy
Phase 1
Yes
Metformin, Rosuvastatin, ALXN2080
All
20
Interventional
18 Years - 55 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 May 2024 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 On Day 1, all participants will receive a single oral dose (fasted) of Metformin followed by a single oral dose (fasted) of Rosuvastatin on Day 3. | Drug: Metformin Participants will receive Metformin orally, after fasting. Drug: Rosuvastatin Participants will receive Rosuvastatin orally, after fasting. |
Experimental: Cohort 2 All participants will receive ALXN2080 twice daily (BID) on Day 1 to Day 11. On the morning of Day 6, participants will be given a single dose of Metformin co-administered with the morning dose of ALXN2080. On the morning of Day 8, participants will be given a single dose of Rosuvastatin co-administered with the morning dose of ALXN2080. | Drug: Metformin Participants will receive Metformin orally, after fasting. Drug: Rosuvastatin Participants will receive Rosuvastatin orally, after fasting. Drug: ALXN2080 Participants will receive ALXN2080 orally, after fasting. |